Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 20


Mir-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma.

Nymoen DA, Slipicevic A, Holth A, Emilsen E, Falkenthal TE, Tropé CG, Reich R, Flørenes VA, Davidson B.

Hum Pathol. 2016 Apr 7. pii: S0046-8177(16)30025-9. doi: 10.1016/j.humpath.2016.03.010. [Epub ahead of print]


Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma.

Magnussen GI, Emilsen E, Giller Fleten K, Engesæter B, Nähse-Kumpf V, Fjær R, Slipicevic A, Flørenes VA.

BMC Cancer. 2015 Jun 10;15:462. doi: 10.1186/s12885-015-1474-8.


Expression of CDK1(Tyr15), pCDK1(Thr161), Cyclin B1 (total) and pCyclin B1(Ser126) in vulvar squamous cell carcinoma and their relations with clinicopatological features and prognosis.

Wang Z, Slipicevic A, Førsund M, Trope CG, Nesland JM, Holm R.

PLoS One. 2015 Apr 7;10(4):e0121398. doi: 10.1371/journal.pone.0121398. eCollection 2015.


Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma.

Flørenes VA, Emilsen E, Dong HP, Førsund M, Holm R, Slipicevic A.

Cancer Med. 2015 Jun;4(6):903-13. doi: 10.1002/cam4.425. Epub 2015 Feb 7.


KIT in melanoma: many shades of gray.

Slipicevic A, Herlyn M.

J Invest Dermatol. 2015 Feb;135(2):337-8. doi: 10.1038/jid.2014.417.


Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells.

Webster MR, Xu M, Kinzler KA, Kaur A, Appleton J, O'Connell MP, Marchbank K, Valiga A, Dang VM, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W 3rd, Becker KG, Kossenkov AV, Frederick DT, Flaherty KT, Xu X, Herlyn M, Murphy ME, Weeraratna AT.

Pigment Cell Melanoma Res. 2015 Mar;28(2):184-95. doi: 10.1111/pcmr.12330. Epub 2014 Dec 29.


Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.

Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA.

Gynecol Oncol. 2014 Oct;135(1):118-24. doi: 10.1016/j.ygyno.2014.07.102. Epub 2014 Aug 2.


Isolation of melanoma cell subpopulations using negative selection.

Slipicevic A, Somasundaram R, Sproesser K, Herlyn M.

Methods Mol Biol. 2014;1102:501-12. doi: 10.1007/978-1-62703-727-3_26.


Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis.

Slipicevic A, Øy GF, Rosnes AK, Stakkestad Ø, Emilsen E, Engesæter B, Mælandsmo GM, Flørenes VA.

Cancer Biol Ther. 2013 Feb;14(2):146-54. doi: 10.4161/cbt.22953. Epub 2012 Nov 28.


High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy.

Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A, Flørenes VA.

PLoS One. 2012;7(6):e38254. doi: 10.1371/journal.pone.0038254. Epub 2012 Jun 12.


Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival.

Slipicevic A, Holm R, Emilsen E, Ree Rosnes AK, Welch DR, Mælandsmo GM, Flørenes VA.

BMC Cancer. 2012 Feb 22;12:73. doi: 10.1186/1471-2407-12-73.


Narrowing the knowledge gaps for melanoma.

Slipicevic A, Herlyn M.

Ups J Med Sci. 2012 May;117(2):237-43. doi: 10.3109/03009734.2012.658977. Epub 2012 Feb 16. Review.


Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma.

Oy GF, Slipicevic A, Davidson B, Solberg Faye R, Maelandsmo GM, Flørenes VA.

Int J Cancer. 2010 Jan 15;126(2):350-61. doi: 10.1002/ijc.24727.


Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.

Slipicevic A, Øy GF, Askildt IC, Holth A, Hellesylt E, Flørenes VA, Davidson B.

Hum Pathol. 2009 Apr;40(4):527-37. doi: 10.1016/j.humpath.2008.10.003. Epub 2009 Jan 3.


The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells.

Slipicevic A, Jørgensen K, Skrede M, Rosnes AK, Trøen G, Davidson B, Flørenes VA.

BMC Cancer. 2008 Sep 30;8:276. doi: 10.1186/1471-2407-8-276.


Fli-1 expression in malignant melanoma.

Torlakovic EE, Slipicevic A, Flørenes VA, Chibbar R, DeCoteau JF, Bilalovic N.

Histol Histopathol. 2008 Nov;23(11):1309-14.


Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma.

Davidson B, Hadar R, Schlossberg A, Sternlicht T, Slipicevic A, Skrede M, Risberg B, Flørenes VA, Kopolovic J, Reich R.

Hum Pathol. 2008 Jan;39(1):87-95. Epub 2007 Oct 18.


Pax-5 expression in nonhematopoietic tissues.

Torlakovic E, Slipicevic A, Robinson C, DeCoteau JF, Alfsen GC, Vyberg M, Chibbar R, Flørenes VA.

Am J Clin Pathol. 2006 Nov;126(5):798-804.


Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome.

Slipicevic A, Holm R, Nguyen MT, Bøhler PJ, Davidson B, Flørenes VA.

Am J Clin Pathol. 2005 Oct;124(4):528-36.


Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2.

Jørgensen K, Skrede M, Cruciani V, Mikalsen SO, Slipicevic A, Flørenes VA.

Biochem Biophys Res Commun. 2005 Apr 1;329(1):266-74.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk